{"id":735035,"date":"2021-04-16T11:30:00","date_gmt":"2021-04-16T11:30:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=f4ac1eea7f53388725643118bb211340"},"modified":"2021-04-16T11:30:00","modified_gmt":"2021-04-16T11:30:00","slug":"new-data-at-aan-2021-from-across-biogens-ms-portfolio-demonstrate-positive-impact-of-treatment-on-people-living-with-relapsing-multiple-sclerosis-2","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/new-data-at-aan-2021-from-across-biogens-ms-portfolio-demonstrate-positive-impact-of-treatment-on-people-living-with-relapsing-multiple-sclerosis-2\/","title":{"rendered":"New Data at AAN 2021 from Across Biogen\u2019s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis"},"content":{"rendered":"<p><![CDATA[CAMBRIDGE, Mass., April  16, 2021  (GLOBE NEWSWIRE) -- Biogen Inc.\u00a0(Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI\u00ae (natalizumab) as well as new real-world experience data from VUMERITY\u00ae (diroximel fumarate). The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71361],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/735035"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=735035"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/735035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=735035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=735035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=735035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}